Assessment of availability of assisted reproductive technologies in Ukraine and the world
In Ukraine, in order to achieve the Sustainable Development Goals, the State Strategy for the Implementation of the State Policy for the Provision of the Population with Medicines for the Period until 2025 has been approved, which includes improving the availability of drugs to improve the quality of life. Assisted Reproductive Technologies (ART) are gaining widespread implementation and funding from the budget in the world.
Goal – the aim of the work was to analyze the state and dynamics of ART cycles in Ukraine for 1999–2019 and to estimate the cost of ART in Ukraine and to develop a methodology for estimating the availability of ART and comparison with European countries.
Materials – international and domestic publications on the assessment of the availability of drugs, the cost of ART. Research methods: system analysis, data synthesis and generalization of information, webometric analysis, statistical analysis of data on the number of ART cycles for 1999-2018, analysis of ART costs.
It is determined that the indicator of the number of ART cycles per 1 million population increased 29.9 times for 1999–2018, which is due to the increase in the number of ART centers conducted ART cycles in relation to the decrease in the population of Ukraine.
It was found that 85% of ART centers are concentrated in only 4 cities (Kyiv, Lviv, Odessa, Kharkiv), which reduces the accessibility of the population to ART cycles, especially in the conditions of quarantine and pandemic COVID-19. It was found that in 1999–2018 the number of ART centers increased 7.7 times, but only 10.8% of ART centers have state funding, which indicates the low availability of ART for budget funds.
It was found that the structure of ART cycles changed significantly. The average costs for the most common ART cycles IVF and ICSI in Ukraine as of the end of 2019 have been determined. It has been shown that only 26% of ART centers provide information on the cost of ART cycles, and web pages need to be filled with information on the cost of ART cycles to ensure that patients are properly informed.
It is shown that in Ukraine as of 2020 the costs of ART cycles are 24 425–30 516 UAH (917,25–1 010,57 Euro) depending on the type of cycle from the perspective of the payer. It is estimated that the availability of ART is 1.5–9.98 depending on the type of ART cycle, the cost of ART cycles is 6–10 times higher than the average family income, when in European countries the availability of ART is much lower 1,5–4.2, which showed higher availability of ART in European countries from payer prospect.
Sustainable Development Goals. Available from: https://www.undp.org/content/undp/en/home/sustainable-development-goals.html
Niëns L. M., Van de Poel E., Cameron A. et al. Practical measurement of affordability: an application to medicines // Bull. World Health Organ. – 2012. – V. 90, N 3. –P. 219–227. https://doi.org/10.2471/BLT.10.084087
Niëns L. M., Brouwer W. B. F. Better measures of affordability required // Lancet. – 2009. – V. 373. – P. 1081–1082. https://doi.org/10.1016/S0140-6736(09)60649-8
Measuring medicine prices, availability, affordability and price components. 2nd ed. Geneva: World Health Organization & Health Action International; 2008 (WHO/PSM/PAR/2008.3). Available from: https://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf?ua=1
O'Donnell O., van Doorslaer E., Wagstaff A., Lindelow M. Analyzing health equity using household survey data: a guide to techniques and their implementation. – Washington: World Bank, 2008. Available from: http://books.google.ch/books?id=8krsjfKv2vgC&printsec=frontcover&hl=de&source=gbs_ge_summary_r&cad= 0#v=onepage&q&f=false
Availability of medicines. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/availability-medicines
Mnushko Z. N., Chmikhalo N. V., Musyenko N. M. i dr. Mezhdunarodnii marketynh v farmatsyy. – Kharkiv: Vyd-vo NFaU: Zoloti storinky, 2006. – 522 s.
Nemchenko A. S., Kurylenko Yu. Ye. Marketynhovi doslidzhennia farmatsevtychnoho rynku likarskykh zasobiv dlia likuvannia sertsevo-sudynnykh zakhvoriuvan // Farmats. chasopys. – 2018. – № 2. – S. 77–81.
Kukhtenko O. S., Nazarkina V. M., Hladukh Ye. V. Farmakoekonomichna otsinka dostupnosti likarskykh zasobiv dlia likuvannia zakhvoriuvan dykhalnykh shliakhiv // Farmats. chasopys. – 2017. – № 3. – S. 105–111.
Derzhavna stratehiia realizatsii derzhavnoi polityky zabezpechennia naselennia likarskymy zasobamy na period do 2025 roku. – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/1022-2018-%D0%BF#Text
Infohrafichnyi dovidnyk «Farmatsevtyka Ukrainy», 2019. – Rezhym dostupu: https://eba.com.ua/infografichnyj-dovidnyk-farmatsevtyka-ukrayiny-2019/
MOZ Ukrainy Otsinka medychnykh tekhnolohii. – Rezhym dostupu: https://moz.gov.ua/article/news/moz-ukraini-zaprovadzhue-vikoristannja-ocinki-medichnih-tehnologij
Adamson G. D. Global cultural and socioeconomic factors that influence access to assisted reproductive technologies // Womens Health. – 2009. – V. 5, N 4. – P. 351–358. https://doi.org/10.2217/whe.09.28. Available from: https://journals.sagepub.com/doi/10.2217/WHE.09.28
Collins J. An international survey of the health economics of IVF and ICSI // Hum. Reprod. Update.– 2002. – V. 8, N 3. – P. 265–277. https://doi.org/10.1093/humupd/8.3.265
Teoh P. J., Maheshwar A. Low-cost in vitro fertilization: current insights // Int. J. Womens Health. – 2014. – V. 6. – P. 817–827. https://doi.org/10.2147/IJWH.S51288
Connolly M., Hoorens J., Chambers G. M. The costs and consequences of assisted reproductive technology: an economic perspective // Hum. Reprod. Update. – 2010. – V. 16, Issue 6. – P. 603–613. https://doi.org/10.1093/humupd/dmq013
Chambers G. M., Sullivan E. A., Ishihara O. et al. The economic impact of assisted reproductive technology: a review of selected developed countries // Fertil. Steril. – 2009. V. 91, N 6. – P. 2281–2294. https://doi.org/10.1016/j.fertnstert.2009.04.029
Bitler M., Schmidt L. Health disparities and infertility: impacts of state-level insurance mandates // Fertil. Steril. – 2006. V. 85. – P. 858–865. https://doi.org/10.1016/j.fertnstert.2005.11.038
Hammoud A. O, Gibson M., Stanford J. et al. In vitro fertilization availability and utilization in the United States: a study of demographic, social, and economic factors // Fertil. Steril. – 2009. – V. 91. – P. 1630–1635. https://doi.org/10.1016/j.fertnstert.2007.10.038
European Society of Human Reproduction and Embryology. Available from: https://www.eshre.eu/-/media/sitecore-files/Press-room/Resources/4-Reimbursement.pdf?la=en&hash=C714A51012C21CCD5C475982A8BC18DDD0586806
Chambers G. M., Hoang V. P., Sullivan E. A. et al. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: An international analysis // Fertil. Steril. – 2014. – V. 101. – P. 191–198. https://doi.org/10.1016/j.fertnstert.2013.09.005
Berg Brigham K., Cadler B., Chevreul K. The diversity of regulation and public financing of IVF in Europe and its impact on utilization // Hum. Reprod. – 2013. – V. 28. – P. 666–675. https://doi.org/10.1093/humrep/des418
Nakaz MOZ vid 10. 07. 2004 № 579 "Pro zatverdzhennia Poriadku napravlennia zhinok dlia provedennia pershoho kursu likuvannia bezplidnosti metodamy dopomizhnykh reproduktyvnykh tekhnolohii za absoliutnymy pokazanniamy za biudzhetni koshty". – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/z0224-05
Nakaz MOZ Ukrainy vid 09. 09. 2013 № 787 "Pro zatverdzhennia Poriadku zastosuvannia dopomizhnykh reproduktyvnykh tekhnolohii v Ukraini". – Rezhym dostupu: https://zakon.rada.gov.ua/laws/show/z1697-13
Ukrainska asotsiatsiia reproduktyvnoi medytsyny. – Rezhym dostupu: http://www.uarm.org.ua/
IVF abroad patient’s guide / Europe 2020. Available from: https://www.whereivf.com/
This work is licensed under a Creative Commons Attribution 4.0 International License.